What is GLP-2 (TZ) and where does it come from?

GLP-2 (TZ) is a synthetic analog of glucagon-like proteide-2, a 33-amino-acid hormone the gut naturally secretes after meals. Its research interest lies in signaling the intestinal lining to grow and repair. The (TZ) designation refers to a stabilized version designed to resist rapid enzymatic breakdown.

What has research shown about GLP-2?

In animal studies, GLP-2 increased the height and mass of the small-intestine lining and improved nutrient uptake. Preclinical short bowel syndrome models are the main context, where researchers investigate whether a longer-acting analog can help a shortened gut absorb more. These are laboratory findings and are not claims about effects in people.

Is GLP-2 (TZ) FDA approved?

GLP-2 (TZ) itself is not an approved drug. A related GLP-2 analog, teduglutide (Gattex/Revestive), is approved for short bowel syndrome, but that is a separate finished pharmaceutical. The material sold here is research-grade and supplied for in-vitro and laboratory research use only — not for human or veterinary use.

How does GLP-2 differ from the natural hormone?

Native GLP-2 is broken down within minutes by the enzyme DPP-4, which limits its usefulness in research. Analogs like this one are engineered to last longer, giving a more stable signal window for study. That extended activity is a key reason researchers prefer analogs over the native peptide in the lab.

What is the molecular structure of GLP-2 (TZ)?

It has the molecular formula C225H348N48O68 and a molecular weight of 4813.45 g/mol, with CAS number 2023788-19-2. The defining feature is its peptide backbone — a chain of amino acids based on GLP-2, modified for stability. Every lot is confirmed by LC-MS for identity and assayed at ≥99% purity by HPLC-UV.

GLP-2 (TZ)

The gut-lining peptide that regrows intestinal tissue in studies

99.96% pure on this exact lot, verified by an independent lab, not by us
Tested in America. Ships within 1 business day, stored frozen, stable at room temperature until you mix it
Retest it at any lab. If it doesn't match our report, every dollar back

$139/ 30mg vial

$69.50 per vial with Buy 1, Get 1 Free

Size: 30mg

Buy 1, Get 1 Free — add 2 to cart, applied automatically

In stock

99.96% pure on this exact lot, verified by an independent lab, not by us
Tested in America. Ships within 1 business day, stored frozen, stable at room temperature until you mix it
Retest it at any lab. If it doesn't match our report, every dollar back

VISAAMEXPayPal

Secure checkout

All products currently listed on this site are for research purposes only.

Frequently bought together

Related laboratory supplies.

Reconstitution Solution · 3ml

Essential

GHK-Cu · 50mg

Melanotan II · 10mg

Add all (3)$97

Certificate of analysis

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity
Raw chromatogram + mass confirmation attached
Signed off by the lab's Principal Chemist
Permanent archive — searchable by lot ID

or browse the lot archive

GLP-2 (TZ) · 30mgLot BAV6Y2Live

Purity by HPLC-UV

99.96%

Tested by: Freedom Diagnostics
Tested on: 21 Sept 2026
Net content: 29.81 mg

Contaminant screens

Heavy metalsEndotoxinsMicrobialSolvents

See all lab reports

Live batch data

Freedom Diagnostics

Independent analytical lab

Certificate of Analysis

RESULT · PASS

Lot BAV6Y2Verified

GLP-2 (TZ) 30mg

HPLC purity

99.96%

Pass · Meets spec

Tested

21 Sept 2026

HPLC-UV + LC-MS

Analytical results

Identity (LC-MS)ConfirmedPASS

Net content29.81 mgPASS

HPLC Chromatogram

Main peak 99.96% · other 0.04%

Alex JohnsonPrincipal Chemist

Authentichain · Verified 108×

Gut growthGLP-2 receptor

Absorptionmucosal surface

Barrier repairepithelial integrity

How GLP-2 (TZ) works

GLP-2 is studied to act through three routes that together drive gut lining maintenance and repair.

Gut growthGLP-2 receptor

It binds the GLP-2 receptor on gut cells, a signal studied for triggering the intestinal lining to grow taller and thicker.

Absorptionmucosal surface

By expanding the absorptive surface of the intestine, it is studied for helping the gut pull more nutrients and fluid from food.

Barrier repairepithelial integrity

It is investigated for strengthening the gut barrier and slowing lining cell death, which may support recovery of damaged tissue.

For research use only. Mechanisms described reflect published preclinical and clinical literature.

Every batch we've tested

Anyone can show you one good report. Here is every batch of GLP-2 (TZ) we have ever released, newest first, each with its own signed report. Nothing hidden, nothing cherry-picked.

15 batches on record · latest tested 21 Sept 2026

All lab reportsEvery GLP-2 (TZ) batch, on one page.The full testing history with every signed report. No login, no email wall.See all lab reports

What the studies found

Published findings on this compound, each linked to its source. Animal and lab results are context, not claims about this product.

Body weightClinical

−20.9%

In a 72-week trial of 2,539 adults with obesity, those on the highest tirzepatide dose lost an average of 20.9% of their body weight.

vs −3.1% on placebo

NEJM 2022 · SURMOUNT-1 RCT, n=2,539

Placebo−3.1%

Low dose−15.0%

Mid dose−19.5%

High dose−20.9%

Mean change in body weight at 72 weeks

Head-to-headClinical

−20.2%

In a 72-week head-to-head trial of 751 adults with obesity, those on tirzepatide lost 20.2% of their body weight, vs 13.7% on semaglutide.

vs −13.7% on semaglutide

Semaglutide−13.7%

Tirzepatide−20.2%

Mean change in body weight at 72 weeks

NEJM 2025 · SURMOUNT-5 RCT, n=751

Heart failureClinical

−38%

In 731 adults with obesity and heart failure with preserved pumping, tirzepatide cut the risk of heart death or worsening heart failure by 38% over a median 104 weeks.

9.9% vs 15.3% on placebo

Heart death or worse heart failure0.62

Worsening heart failure0.54

No effect

Hazard ratio vs placebo, median 104 weeks

NEJM 2025 · SUMMIT RCT, n=731